CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top player positioning

3.3. Market Dynamics

3.3.1. Drivers

3.3.1.1. Increase in prevalence of atrial fibrillation, venous thromboembolism and stroke
3.3.1.2. Rise in number of geriatric population
3.3.1.3. Increase in prevalence of obesity
3.3.1.4. Surge in healthcare expenditures worldwide

3.3.2. Restraints

3.3.2.1. High price of NOACs
3.3.2.2. Poor demand in under developed countries

3.3.3. Opportunity

3.3.3.1. Increase in demand for NOACs
3.3.3.2. Growth opportunities in emerging markets

3.3.4. Impact Analyses

CHAPTER 4: ANTICOAGULANTS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. NOACs

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Eliquis market size and forecast
4.2.2.2. Bevyxxa market size and forecast
4.2.2.3. Xarelto market size and forecast
4.2.2.4. Savaysa & Lixiana market size and forecast
4.2.2.5. Pradaxa market size and forecast

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Heparins & LMWH

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Vitamin K Antagonists

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Other Anticoagulant Drugs

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral Anticoagulants

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Injectable Anticoagulants

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

CHAPTER 6: ANTICOAGULANTS MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Atrial Fibrillation & Heart Attack

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Stroke

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

6.4. Deep Vein Thrombosis (DVT)

6.4.1. Market size and forecast
6.4.2. Market analysis, by country

6.5. Pulmonary Embolism (PE)

6.5.1. Market size and forecast
6.5.2. Market analysis, by country

6.6. Others

6.6.1. Market size and forecast
6.6.2. Market analysis, by country

CHAPTER 7: ANTICOAGULANTS MARKET BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. anticoagulants market, by drug class
7.2.2.1.2. U.S. anticoagulants market, by route of administration
7.2.2.1.3. U.S. anticoagulants market, by application

7.2.2.2. Canada

7.2.2.2.1. Canada anticoagulants market, by drug class
7.2.2.2.2. Canada anticoagulants market, by route of administration
7.2.2.2.3. Canada anticoagulants market, by application

7.2.2.3. Mexico

7.2.2.3.1. Mexico anticoagulants market, by drug class
7.2.2.3.2. Mexico anticoagulants market, by route of administration
7.2.2.3.3. Mexico anticoagulants market, by application

7.2.3. North America anticoagulants market, by drug class
7.2.4. North America anticoagulants market, by route of administration
7.2.5. North America anticoagulants market, by application

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Germany anticoagulants market, by drug class
7.3.2.1.2. Germany anticoagulants market, by route of administration
7.3.2.1.3. Germany anticoagulants market, by application

7.3.2.2. France

7.3.2.2.1. France anticoagulants market, by drug class
7.3.2.2.2. France anticoagulants market, by route of administration
7.3.2.2.3. France anticoagulants market, by application

7.3.2.3. UK

7.3.2.3.1. UK anticoagulants market, by drug class
7.3.2.3.2. UK anticoagulants market, by route of administration
7.3.2.3.3. UK anticoagulants market, by application

7.3.2.4. Italy

7.3.2.4.1. Italy anticoagulants market, by drug class
7.3.2.4.2. Italy anticoagulants market, by route of administration
7.3.2.4.3. Italy anticoagulants market, by application

7.3.2.5. Spain

7.3.2.5.1. Spain anticoagulants market, by drug class
7.3.2.5.2. Spain anticoagulants market, by route of administration
7.3.2.5.3. Spain anticoagulants market, by application

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe anticoagulants market, by drug class
7.3.2.6.2. Rest of Europe anticoagulants market, by route of administration
7.3.2.6.3. Rest of Europe anticoagulants market, by application

7.3.3. Europe anticoagulants market, by drug class
7.3.4. Europe anticoagulants market, by route of administration
7.3.5. Europe anticoagulants market, by application

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Japan anticoagulants market, by drug class
7.4.2.1.2. Japan anticoagulants market, by route of administration
7.4.2.1.3. Japan anticoagulants market, by application

7.4.2.2. China

7.4.2.2.1. China anticoagulants market, by drug class
7.4.2.2.2. China anticoagulants market, by route of administration
7.4.2.2.3. China anticoagulants market, by application

7.4.2.3. Australia

7.4.2.3.1. Australia anticoagulants market, by drug class
7.4.2.3.2. Australia anticoagulants market, by route of administration
7.4.2.3.3. Australia anticoagulants market, by application

7.4.2.4. India

7.4.2.4.1. India anticoagulants market, by drug class
7.4.2.4.2. India anticoagulants market, by route of administration
7.4.2.4.3. India anticoagulants market, by application

7.4.2.5. South Korea

7.4.2.5.1. South Korea anticoagulants market, by drug class
7.4.2.5.2. South Korea anticoagulants market, by route of administration
7.4.2.5.3. South Korea anticoagulants market, by application

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Rest of Asia-Pacific anticoagulants market, by drug class
7.4.2.6.2. Rest of Asia-Pacific anticoagulants market, by route of administration
7.4.2.6.3. Rest of Asia-Pacific anticoagulants market, by application

7.4.3. Asia-Pacific anticoagulants market, by drug class
7.4.4. Asia-Pacific anticoagulants market, by route of administration
7.4.5. Asia-Pacific anticoagulants market, by application

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil anticoagulants market, by drug class
7.5.2.1.2. Brazil anticoagulants market, by route of administration
7.5.2.1.3. Brazil anticoagulants market, by application

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia anticoagulants market, by drug class
7.5.2.2.2. Saudi Arabia anticoagulants market, by route of administration
7.5.2.2.3. Saudi Arabia anticoagulants market, by application

7.5.2.3. South Africa

7.5.2.3.1. South Africa anticoagulants market, by drug class
7.5.2.3.2. South Africa anticoagulants market, by route of administration
7.5.2.3.3. South Africa anticoagulants market, by application

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA anticoagulants market, by drug class
7.5.2.4.2. Rest of LAMEA anticoagulants market, by route of administration
7.5.2.4.3. Rest of LAMEA anticoagulants market, by application

7.5.3. LAMEA anticoagulants market, by drug class
7.5.4. LAMEA anticoagulants market, by route of administration
7.5.5. LAMEA anticoagulants market, by application

CHAPTER 8: COMPANY PROFILES

8.1. Aspen Holdings

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance

8.2. Bayer AG

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance

8.3. Boehringer Ingelheim Pharma GmbH & Co. KG

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance

8.4. Bristol-Myers Squibb Company

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Daiichi Sankyo Co., Ltd.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product Portfolio
8.5.4. Business performance

8.6. GlaxoSmithKline plc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Pfizer Inc.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance

8.9. Portola Pharmaceuticals, Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Key strategic moves and developments

8.10. Sanofi

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance